


JOINT EVENT ON

20th Euro-Global Summit on**Cancer Therapy & Radiation Oncology**

and

2nd International Oncologist & Diagnostics Conference

August 28-30, 2017 Brussels, Belgium

**Wassil Nowicky***Ukrainian Anticancer Institute, Austria***Selective and immunomodulating properties of the anticancer proton preparation on basis of greater celandine alkaloids NSC631570**

One of the most significant problems of cancer therapy is the damaging activity of anticancer drugs against normal body cells. All attempts to develop a therapeutic agent with a selective cytotoxic effect on tumor cells had no much success because of the high degree of biological identity between healthy and malignant cells. The celandine is being used in the medicine over more than 3500 years. The first data concerning the therapeutic effect of the juice of celandine in the patient with malignant melanoma were published in Germany in 1536. From that time drugs based on biologically active substances of celandine are widely used to treat cancer and non-cancer disease. It is well known that tumor cell is more negatively charged as compared to normal cell. We have used this feature of the tumor cell to give NSC631570 a property to selectively interact with it, without endangering healthy cells and tissues. The drug is strongly positively charged. Due to this it has an ability to be selectively accumulated in tumor tissue and to induce tumor cell apoptosis only in tumor cells without harmful effect on normal cells. Potent selective antitumor effect of NSC631570 repeatedly proven by the results of clinical trials. There is an assumption that the same high selective cytotoxicity of drug on tumor cells of different origin is the result of its interaction with an ubiquitous tumor-specific (or overexpressed in tumor cells) compound involved in the induction of cell death. However, this compound remains to be found.

Biography

Wassil Nowicky received degree of Dr. Sci. Tech at the University of Vienna. He is the Director of Nowicky Farma and the Inventor of the Anticancer Preparation NSC631570. He is a Real Member of the New York Academy of Sciences, Member of the European Union for Applied Immunology and of the American Association for Scientific Progress, Honorary Doctor of the Janka Kupala University in Hrodno, Doctor "*honoris causa*" of the Open International University on Complex Medicine in Colombo, and Honorary Member of the Austrian Albert Schweitzer Society. He has published more than 49 papers in reputed journals.

dr.nowicky@yahoo.de**Notes:**